Phase 2 Kidney Cancer Trial, Recruiting (NCT07029503)

Phase 2 Kidney Cancer Trial, Recruiting NCT07029503 Sponsor: Karolinska Institutet Condition: Kidney Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07029503 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Kidney Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have signed a written consent form agreeing to take part in the study
You have been diagnosed with heart failure with reduced pumping function (HFrEF) for at least three months before your screening visit
You have had a heart ultrasound (echocardiogram) within the last two years showing that your heart's pumping strength is 40% or less
Your heart failure symptoms are rated as moderate — meaning you have symptoms during everyday activity but are comfortable at rest (this is called New York Heart Association class II or III)
Your heart failure has been treated as fully as possible and has been stable for at least four weeks, using recommended medications and devices as appropriate for your situation
Your kidney function has been measured as significantly reduced (below a certain level) at least once in the past year, and is still below a certain level at the time you join the trial (confirm exact numbers with trial site)

Who may not be able to join:

Your blood potassium level is too high (confirm threshold with trial site)
Your kidney function is too low or is expected to decline too much during the 36-week study (the exact cut-off may depend on how early you join the trial — confirm with trial site)
You are currently on dialysis or dialysis is planned for you
Your blood pressure is too low (below 90 mmHg at the top number)
Your blood pressure is too high and not well controlled, as assessed by the doctor running the trial
You have severe liver disease
You have had a heart transplant, are planning one, or are planning to have a mechanical heart pump (left ventricular assist device) fitted
You are pregnant, planning to become pregnant, breastfeeding, or unwilling to use highly effective contraception during the trial
You have previously had an allergic reaction to a type of medication called an MRA or a potassium binder
You are currently taking certain medications that could interact with the study drug, including lithium, cyclosporine, tacrolimus, anti-inflammatory painkillers (NSAIDs), trimethoprim, or certain antifungal, antiviral, antibiotic, anti-seizure, or herbal medicines including St. John's Wort (confirm full list with trial site)
You have a specific heart rhythm abnormality on your ECG, a history of a drug causing dangerous heart rhythm problems, or a inherited condition called long QT syndrome (confirm with trial site)
You have an uncontrolled irregular heartbeat, as assessed by the doctor running the trial
You were hospitalised for a heart-related reason or had a heart procedure within the four weeks before joining
The trial doctor does not think you are suitable to participate, for example due to serious other illnesses or a life expectancy of less than 12 months
You have already taken part in this trial before, or are currently in another study that has not been approved to run alongside this one

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Krister Lindmark, MD, PhD, Karolinska Institutet

Phone: 0046735574724

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07029503

Sponsor: Karolinska Institutet

Phase: Phase 2

Status: Recruiting

Condition: Kidney Cancer

Trial contact: 0046735574724

More information: https://clinicaltrials.gov/study/NCT07029503

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have signed a written consent form agreeing to take part in the study
You have been diagnosed with heart failure with reduced pumping function (HFrEF) for at least three months before your screening visit
You have had a heart ultrasound (echocardiogram) within the last two years showing that your heart's pumping strength is 40% or less
Your heart failure symptoms are rated as moderate — meaning you have symptoms during everyday activity but are comfortable at rest (this is called New York Heart Association class II or III)
Your heart failure has been treated as fully as possible and has been stable for at least four weeks, using recommended medications and devices as appropriate for your situation
Your kidney function has been measured as significantly reduced (below a certain level) at least once in the past year, and is still below a certain level at the time you join the trial (confirm exact numbers with trial site)

Who may not be able to join:

Your blood potassium level is too high (confirm threshold with trial site)
Your kidney function is too low or is expected to decline too much during the 36-week study (the exact cut-off may depend on how early you join the trial — confirm with trial site)
You are currently on dialysis or dialysis is planned for you
Your blood pressure is too low (below 90 mmHg at the top number)
Your blood pressure is too high and not well controlled, as assessed by the doctor running the trial
You have severe liver disease
You have had a heart transplant, are planning one, or are planning to have a mechanical heart pump (left ventricular assist device) fitted
You are pregnant, planning to become pregnant, breastfeeding, or unwilling to use highly effective contraception during the trial
You have previously had an allergic reaction to a type of medication called an MRA or a potassium binder
You are currently taking certain medications that could interact with the study drug, including lithium, cyclosporine, tacrolimus, anti-inflammatory painkillers (NSAIDs), trimethoprim, or certain antifungal, antiviral, antibiotic, anti-seizure, or herbal medicines including St. John's Wort (confirm full list with trial site)
You have a specific heart rhythm abnormality on your ECG, a history of a drug causing dangerous heart rhythm problems, or a inherited condition called long QT syndrome (confirm with trial site)
You have an uncontrolled irregular heartbeat, as assessed by the doctor running the trial
You were hospitalised for a heart-related reason or had a heart procedure within the four weeks before joining
The trial doctor does not think you are suitable to participate, for example due to serious other illnesses or a life expectancy of less than 12 months
You have already taken part in this trial before, or are currently in another study that has not been approved to run alongside this one

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Karolinska Institutet

Registry

ClinicalTrials.gov

Start date

1 February 2026

Est. completion

1 February 2027

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

The primary endpoint is the proportion of participants who complete the treatment period with and without the need to use a potassium binder

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov